Select Page

Press

  • Zika envelope is a 'stealth protein'

    Zika envelope is a ‘stealth protein’

    Posted on February 6, 2016 by Annie De Groot
    The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...
    Read more
  • Step into the 21st Century, Novartis!

    Step into the 21st Century, Novartis!

    Posted on February 1, 2016 by Annie De Groot
    (This post has been corrected, thanks Sebastian!) I love “Google Alerts”. They let me know when someone has just published an article citing one of our articles, and link me to new, exciting work that has just been made available on the web. Last week, my google alert linked me to a new paper by Sebastian Spindeldreher’s ...
    Read more
  • New publication in IQT Quarterly

    New publication in IQT Quarterly

    Posted on January 24, 2016 by Annie De Groot
    Our latest mini-publication on ‘vaccines on demand’ can be found here: IQT Quarterly Winter 2016 – EpiVax
    Read more
  • And the winner of a new Hoverboard is . . .

    And the winner of a new Hoverboard is . . .

    Posted on January 24, 2016 by Annie De Groot
    Sancha Salgueiro! Congratulations to Sancha and the team at ExpreS2ion Biotechnologies! https://www.linkedin.com/in/sanchasalgueiro
    Read more
  • Bacteria adopt Immune Camouflage

    Bacteria adopt Immune Camouflage

    Posted on January 23, 2016 by Annie De Groot
    Graduate student Lu He, working with EpiVax CEO De Groot and collaborator Chris Bailey Kellog, recently reported that bacteria ‘copy and paste’ sequences from the human genome to escape immune response. She calls this escape mechanism “bacterial immune camouflage“. She used the JanusMatrix tool to develop a new measure of immune escape,  the Janus Immunogenicity Score ...
    Read more
  • The Immune System Achilles' Heel

    The Immune System Achilles’ Heel

    Posted on January 21, 2016 by Annie De Groot
    An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...
    Read more
  • The Immune System Achilles' Heel

    The Immune System Achilles' Heel

    Posted on January 21, 2016 by Annie De Groot
    An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...
    Read more
  • EpiVax Spins Out Aceno Biotherapeutics at JP Morgan/Biotech Showcase 2016

    Posted on January 11, 2016 by Annie De Groot
    PROVIDENCE, R.I., Jan. 11, 2016 /PRNewswire/ — EpiVax, Inc. (EpiVax) today announced the company’s participation in a new venture, Aceno Biotherapeutics, a BioSuperior company. Co-founder Anne S. De Groot MD will be presenting the vision for the new venture in San Francisco at the Hilton Union Square in San Francisco, at 4 PM (Davidson). Aceno ...
    Read more
  • A Computational Pipeline for Personalized Cancer Vaccines

    A Computational Pipeline for Personalized Cancer Vaccines

    Posted on December 7, 2015 by Annie De Groot
    A short time ago, we received an email that contained an individual patient’s cancer genome. The patient had appealed to his doctor to make a personalized cancer vaccine, and his doctor emailed us, to ask if we could help out. Our answer? Yes we can! A bigger question might be – how will the patient get permission to ...
    Read more
  • Raimondo Works to Spark Innovation Economy

    Posted on November 23, 2015 by Annie De Groot
    Rhode Island offers companies access to research and development to help them grow PROVIDENCE, R.I. – Governor Gina M. Raimondo, along with Secretary of Commerce Stefan Pryor, today launched three new innovation-focused incentive programs aimed at jumpstarting Rhode Island’s economy. Applications for the Innovation Vouchers, Industry Cluster Grants and Innovation Network Matching Grants are now available ...
    Read more
  • EpiVax Accelerating Innovation, Growth

    EpiVax Accelerating Innovation, Growth

    Posted on November 17, 2015 by Annie De Groot
    Seventeen years ago EpiVax Inc. spun out of a laboratory at Brown University – a high-risk but high-reward company whose founders had made an innovative discovery. Today the self-funded, Providence-headquartered company is at the forefront of vaccine research. Its computational tools enable developers to engineer and design safe, effective and protective therapeutic proteins and vaccines, and ...
    Read more
  • EpiVax vaccine technologies get big boost

    Posted on November 2, 2015 by Annie De Groot
    A new blue ribbon study, “A National Blueprint for Biodefense,” endorsed a new strategic direction for medical countermeasures to biothreats, recommending investments in vaccine-on-demand technologies developed by EpiVax. By Richard Asinof WASHINGTON, D.C. – The vaccine on demand technologies pioneered by EpiVax received a major shot in the arm when the Blue Ribbon Study Panel on Biodefense released ...
    Read more
  • Blue Ribbon Biodefense Panel Recommends Vaccines-on-Demand Approach

    Blue Ribbon Biodefense Panel Recommends Vaccines-on-Demand Approach

    Posted on October 28, 2015 by Annie De Groot
    October 28th – Providence, RI – A report released today by former DHS Secretary Tom Ridge, former US Senator Joseph Lieberman and members of the Blue Ribbon Study Panel on Biodefense (BRSPB) identified “serious gaps and inadequacies that continue to leave the Nation vulnerable to biothreats”. Their comprehensive report on the state of National Biodefense calls ...
    Read more
  • A BioBetter Botulinum

    A BioBetter Botulinum

    Posted on October 26, 2015 by Annie De Groot
    Ipsen and EpiVax have announced the completion of a collaborative project that resulted in a “stealth” version of a botulinum neurotoxin derived therapeutic. As foreign proteins, BoNTs have the potential to elicit an immune response reducing therapeutic efficacy. Ipsen is actively developing a platform of novel neurotoxin derived therapeutics, including targeted secretion inhibitors (TSI) that are opening up ...
    Read more
  • Back to the Future: iCubed (URI) hosts its 9th Vaccine Renaissance Conference

    Back to the Future: iCubed (URI) hosts its 9th Vaccine Renaissance Conference

    Posted on October 22, 2015 by Annie De Groot
    Even though Ebola has faded into the background, newly emerging infectious disease remain a challenge for the future. Completely new vaccines to prevent infectious diseases, and ancient ones, will be the focus of this year’s edition of the Vaccine Renaissance. For example, Dr. Steven Hoffman of Sanaria will describe clinical trials with his irradiated Malaria ...
    Read more

Join our newsletter

We strive to provide our clients, collaborators and everyday immunology enthusiasts with valuable content.  Written by our CEO/CSO Dr. Anne Dr Groot, you can expect up to date vaccine development efforts, upcoming events and so much more from our offices here in Providence, RI.

Click Here